- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01785147
Efficacy and Safety of BP1.4979 in Smoking Cessation
Randomized Placebo Controlled Trial Assessing the Efficacy and Safety of BP1.4979 in Smoking Cessation
Study Overview
Detailed Description
BP1.4979 is a novel compound with promising efficacy on smoker which have been assessed on phase I studies.
This is a multicenter,randomized, double blind, placebo controlled, phase IIb trial with parallel group to assess safety and efficacy of BP1.4979 in smoker.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ile de France
-
Villejuif, Ile de France, France, 94800
- Hopital Paul Brousse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main inclusion Criteria:
- a smoking history of at least 10 years
- subject smoking at least 15 cigarettes per day at the time being and for at least 30 days before selection.
- having already made at least 2 attempts to stop
- with no period of abstinence > 3 months in the previous year
- FTND ≥ 7
Main exclusion Criteria:
- any significant psychiatric illness or mood disorder, assessed by the BDI
- HAD scale (A + D ≥ 19, the day of the selection and inclusion)
- AUDIT ≥ 8
- subject smoking cigars or pipes exclusively
- subject taking any antismoking medication and/ or Nicotine Replacement Therapy (NRT) in the previous month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BP1.4979 3mg
BP1.4979 3mg during 3 months
|
BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
|
Experimental: BP1.4979 10mg
BP1.4979 10mg during 3 months
|
BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
|
Experimental: BP1.4979 15mg
BP1.4979 15mg during 3 months
|
BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
|
Placebo Comparator: Placebo
Placebo during 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
4-week prolonged abstinence from smoking cigarettes
Time Frame: 4 weeks
|
The primary measure of efficacy will be 4-week prolonged abstinence from smoking cigarettes at the end of 12-week double-blind treatment phase (i.e. from V3 to V4). The continuous abstinence measured by subject diary and verified by exhaled CO (abstinent < 10 ppm) will define response to the treatment. |
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-day tobacco Point Prevalence Abstinence (PPA)
Time Frame: 7 days
|
7-day tobacco Point Prevalence Abstinence (PPA) will be assessed at each visit by analysis of cigarettes consumption using self-report diaries and measurement of exhaled CO
|
7 days
|
Number of adverse events
Time Frame: 26 weeks
|
Assessment of safety thanks to the number and clinical evaluation of the adverse events.
|
26 weeks
|
Vital signs measures
Time Frame: 26 weeks
|
Vital signs (measurement of heart rate, blood pressure, and body weight) will be assessed at each study visit, thanks to physical examinations (V0 and V4), ECG and laboratory tests (blood chemistry, haematology, urinanalysis tests, prolactin dosage) at screening (V0), after 4-week treatment (V2) and at V4.
|
26 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henri-Jean AUBIN, MD, Ph.D, Hopital Paul Brousse
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P12-01 / BP1.4979
- 2012-002731-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Addiction
-
University of Southern CaliforniaIllinois Institute of TechnologyCompleted
-
University of MinnesotaNational Cancer Institute (NCI)CompletedTobacco Addiction | Dual Tobacco UseUnited States
-
University of Southern CaliforniaUniversity of California, San Diego; University of California, Los AngelesTerminatedSmoking Cessation | Cigarette Smoking | Smoking, Tobacco | Cessation, Tobacco | Smoking (Tobacco) AddictionUnited States
-
Universita degli Studi di CataniaCompleted
-
Harvard University Faculty of MedicineNational Institute on Drug Abuse (NIDA)UnknownTobacco AddictionUnited States
-
The University of Hong KongCompleted
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA); Brown University; National Institutes... and other collaboratorsCompletedSmoking (Tobacco) AddictionUnited States
-
My Digital StudyCompletedSmoking Cessation | Tobacco Smoking | Tobacco Use Disorder | Substance Use Disorder | Drug Addiction | Tobacco Dependence | Drug Dependence | Nicotine AddictionUnited States
-
Click Therapeutics, Inc.CompletedSubstance Use Disorder | Drug Addiction | Tobacco Dependence | Drug Dependence | Nicotine AddictionUnited States
-
Population Health Research InstituteRecruitingSmoking Cessation | Smoking (Tobacco) AddictionCanada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States